LRRK2 inhibitors
Small-molecule and antisense LRRK2-pathway inhibitors (e.g. BIIB122 / DNL151) under clinical evaluation.
State of the art
No update yet for LRRK2 inhibitors. An update is a standalone state-of-the-art for the topic — what someone with Parkinson's needs to know about where this approach stands today.
-
Genome-wide association and population-tailored polygenic risk for Parkinson’s disease in Taiwan
The gene-dosage analysis identifies double East-Asian LRRK2 variant carriers (p.G2385R + p.R1628P) as a high-risk subgroup with markedly elevated LRRK2 kinase activity (elevated pRab10 phosphorylation), making them a priority population for stratified trials of type II LRRK2 kinase inhibitors now under development. -
バイオジェンとデナリ、パーキンソン病治療薬の開発を中止 執筆 - Investing.com - FX | 株式市場 | ファイナンス | 金融ニュース
The Phase 2b LUMA trial of BIIB122 (DNL151) — one of the most advanced LRRK2 inhibitor programmes — failed to slow disease progression versus placebo in early-stage idiopathic Parkinson's, leading Biogen and Denali to discontinue development for the general Parkinson's population. The drug did hit its biological targets (>90% peripheral LRRK2 inhibition, ~30% CSF biomarker reduction), suggesting the mechanism itself may be insufficient for broad Parkinson's, though the separate BEACON trial in people with a pathogenic LRRK2 gene variant continues, with data expected in the first half of 2027.